Product Description: Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke[1][2].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]Diana Cash, et al. GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J Neurol Exp Neurosci. 2016;2(2):28-33. Epub 2016 Nov 21./[2]B Abila, et al. First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9.
CAS Number: 1233953-61-1
Molecular Weight: N/A
Research Area: Neurological Disease
Solubility: H2O
Target: Others